Voronoi, Inc.
Financials
Valuation Metrics
Voronoi, Inc.'s Market Cap is ₩1.9T. At end of 2025 it was ₩4.0T. Ranked #195 of 2,410 in KR market (top 8%), #36 of 1,631 on KOSDAQ (top 2%), #16 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.94T KRW | KR#195/2,410 Sec#16/231 |
| Revenue | 4.16B KRW | KR#2,342/2,410 Sec#202/231 |
| Net Income | -69.13B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 133.72B KRW | KR#1,583/2,410 Sec#123/231 |
| Net Assets | 69.18B KRW | KR#1,690/2,410 Sec#142/231 |
| Employees | 147 | KR#1,339/2,410 Sec#108/231 |
| Value | ||
| P/B | 28.01x | KR#2,400/2,410 Sec#229/231 |
| P/S | 465.63x | KR#2,398/2,410 Sec#224/231 |
| FCF Yield | -3.81% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -99.94% | KR#2,335/2,410 Sec#218/231 |
| ROA | -51.70% | KR#2,357/2,410 Sec#216/231 |
| Op. Margin | -1947.05% | KR#2,375/2,410 Sec#220/231 |
| Revenue Growth | 24.23% | KR#468/2,410 Sec#45/231 |
| Financial Health | ||
| Debt Ratio | 93.30% | KR#1,485/2,410 Sec#172/231 |
| Total Debt | 31.05B KRW | KR#1,210/2,410 Sec#90/231 |
| FCF | -73.74B KRW | KR#2,103/2,410 Sec#208/231 |
| Cash | 24.83B KRW | KR#1,116/2,410 Sec#75/231 |
| Current Ratio | 9.46x | KR#110/2,410 Sec#26/231 |
| Performance | ||
| 1Y Return | -46.89% | KR#1,864/2,410 Sec#165/231 |
| 1M Return | -27.76% | KR#1,969/2,410 Sec#200/231 |
| From 52W High | -72.28% | KR#2,097/2,410 Sec#179/231 |
| 1Y MDD | -72.27% | KR#2,054/2,410 Sec#178/231 |
| Trading | ||
| Volume | 46,526 shares | KR#837/2,410 Sec#86/231 |
| Trading Value | 4.88B KRW | KR#227/2,410 Sec#17/231 |
| Foreign Own. | 6.26% | KR#704/2,410 Sec#62/231 |
| Per Share | ||
| EPS | -3,714 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,716 KRW | KR#1,736/2,410 Sec#127/231 |
Company Info
Established in 2015 in Songdo, Incheon, VORONOI is a new drug development venture company with its own medicinal chemistry research institute. It specializes in developing targeted anticancer drugs for conditions like lung and breast cancer, with VRN11 currently undergoing global clinical phase 1 trials after approvals in Korea, Taiwan, and Hong Kong. The company utilizes its Voronomix platform to accelerate drug development from target selection to candidate substance in 1-1.5 years, demonstrating competitiveness through five technology transfer achievements since 2020. VORONOI is headquartered in Yeonsu-gu, Incheon Metropolitan City.